Newly Diagnosed Multiple Myeloma Ndmm clinical trials

Explore recruiting newly diagnosed multiple myeloma ndmm clinical trials.

Recruiting newly diagnosed multiple myeloma ndmm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Newly Diagnosed Multiple Myeloma Ndmm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

Portugal, Spain, Denmark, Austria, Italy, Belgium +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination with Bortezomib (Velcade®), Lenalidomide and Dexamethasone versus Bortezomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Denmark, France, Spain, Czechia, Portugal, Sweden +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open, randomised, controlled phase II trial of CellProtect in combination with Isatuximab antibody versus Isatuximab antibody alone as maintenance treatment in patients with Multiple Myeloma undergoing high dose treatment (ISA-HC-NK)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Isatuximab in combination with Lenalidomide-Dexamethasone compared to Lenalidomide-Dexamethasone in elderly patients (aged ≥70 years) with newly diagnosed myeloma: a randomized phase II study (SGZ-2019-12650)

Austria, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Norway, France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Newly Diagnosed Multiple Myeloma Ndmm trials by city

Newly Diagnosed Multiple Myeloma Ndmm in Toronto Newly Diagnosed Multiple Myeloma Ndmm in Vancouver Newly Diagnosed Multiple Myeloma Ndmm in Montreal Newly Diagnosed Multiple Myeloma Ndmm in Calgary Newly Diagnosed Multiple Myeloma Ndmm in Edmonton Newly Diagnosed Multiple Myeloma Ndmm in Ottawa Newly Diagnosed Multiple Myeloma Ndmm in Winnipeg Newly Diagnosed Multiple Myeloma Ndmm in Quebec City Newly Diagnosed Multiple Myeloma Ndmm in Hamilton Newly Diagnosed Multiple Myeloma Ndmm in Kitchener Newly Diagnosed Multiple Myeloma Ndmm in London Newly Diagnosed Multiple Myeloma Ndmm in Halifax Newly Diagnosed Multiple Myeloma Ndmm in New York Newly Diagnosed Multiple Myeloma Ndmm in Los Angeles Newly Diagnosed Multiple Myeloma Ndmm in Chicago Newly Diagnosed Multiple Myeloma Ndmm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease